日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Longitudinal study of immunity to SARS-CoV2 in ocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination

一项关于接受奥瑞珠单抗治疗的多发性硬化症患者在接种新冠疫苗后长达两年内对SARS-CoV-2免疫力的纵向研究

期刊:Annals of Clinical and Translational Neurology
影响因子:3.9
doi:10.1002/acn3.52081
Kister, Ilya; Curtin, Ryan; Piquet, Amanda L; Borko, Tyler; Pei, Jinglan; Banbury, Barbara L; Bacon, Tamar E; Kim, Angie; Tuen, Michael; Velmurugu, Yogambigai; Nyovanie, Samantha; Selva, Sean; Samanovic, Marie I; Mulligan, Mark J; Patskovsky, Yury; Priest, Jessica; Cabatingan, Mark; Winger, Ryan C; Krogsgaard, Michelle; Silverman, Gregg J
SARS-CoV-2
新冠
神经科学
多发性硬化症
微生物学
免疫/内分泌
发表日期：2024
文献求助 收藏

Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis

居家输注奥瑞珠单抗治疗多发性硬化症的安全性和患者体验

期刊:Annals of Clinical and Translational Neurology
影响因子:3.9
doi:10.1002/acn3.51745
Barrera, Britney; Simpson, Haley; Engebretson, Eric; Sillau, Stefan; Valdez, Brooke; Parra-González, José; Winger, Ryan C; Epperson, Lou Anne; Banks, Ashley; Pierce, Kathryn; Spotts, Melanie; O'Gean, Katie; Alvarez, Enrique; Gross, Robert; Piquet, Amanda L; Schreiner, Teri; Corboy, John R; Pei, Jinglan; Vollmer, Timothy L; Nair, Kavita V
神经科学
多发性硬化症
发表日期：2023
文献求助 收藏

Cellular and Humoral Immunity to SARS-CoV-2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease-Modifying Therapies: A Multi-Ethnic Observational Study.

接受奥瑞珠单抗和其他疾病修饰疗法治疗的多发性硬化症患者的 SARS-CoV-2 感染的细胞和体液免疫：一项多民族观察性研究

期刊:Annals of Neurology
影响因子:7.7
doi:10.1002/ana.26346
Kister Ilya, Patskovsky Yury, Curtin Ryan, Pei Jinglan, Perdomo Katherine, Rimler Zoe, Voloshyna Iryna, Samanovic Marie I, Cornelius Amber R, Velmurugu Yogambigai, Nyovanie Samantha, Kim Joseph J, Tardio Ethan, Bacon Tamar E, Zhovtis Ryerson Lana, Raut Pranil, Pedotti Rosetta, Hawker Kathleen, Raposo Catarina, Priest Jessica, Cabatingan Mark, Winger Ryan C, Mulligan Mark J, Krogsgaard Michelle, Silverman Gregg J
细胞生物学
多发性硬化症
发表日期：2022
文献求助 收藏

Hybrid and vaccine-induced immunity against SAR-CoV-2 in MS patients on different disease-modifying therapies.

接受不同疾病修饰疗法的 MS 患者对 SARS-CoV-2 的混合免疫和疫苗诱导免疫

期刊:Annals of Clinical and Translational Neurology
影响因子:3.9
doi:10.1002/acn3.51664
Kister Ilya, Curtin Ryan, Pei Jinglan, Perdomo Katherine, Bacon Tamar E, Voloshyna Iryna, Kim Joseph, Tardio Ethan, Velmurugu Yogambigai, Nyovanie Samantha, Valeria Calderon Andrea, Dibba Fatoumatta, Stanzin Igda, Samanovic Marie I, Raut Pranil, Raposo Catarina, Priest Jessica, Cabatingan Mark, Winger Ryan C, Mulligan Mark J, Patskovsky Yury, Silverman Gregg J, Krogsgaard Michelle
炎症/感染
新冠
发表日期：2022
文献求助 收藏

Clinical outcomes of patients with giant cell arteritis treated with tocilizumab in real-world clinical practice: decreased incidence of new visual manifestations

真实世界临床实践中，托珠单抗治疗巨细胞动脉炎患者的临床结果：新发视觉症状发生率降低

期刊:Arthritis Research & Therapy
影响因子:4.6
doi:10.1186/s13075-020-02377-8
Unizony, Sebastian; McCulley, Timothy J; Spiera, Robert; Pei, Jinglan; Sidiropoulos, Paris N; Best, Jennie H; Birchwood, Christine; Pavlov, Andrey; Stone, John H
细胞生物学
发表日期：2021
文献求助 收藏

Comparative Cost per Response for 4 Clinical Endpoints with Tocilizumab Monotherapy vs Adalimumab Monotherapy in a Head-to-Head Randomized Double-Blind Superiority Trial (ADACTA) in Patients with Rheumatoid Arthritis

在类风湿性关节炎患者的头对头随机双盲优效性试验 (ADACTA) 中，托珠单抗单药治疗与阿达木单抗单药治疗在 4 个临床终点上的每次反应成本比较

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-019-00191-6
Best, Jennie H; Vlad, Steven C; Pei, Jinglan
关节炎
ACTA
ADA
发表日期：2020
文献求助 收藏

Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data

巨细胞动脉炎和类风湿性关节炎患者人群的不良事件：托珠单抗临床试验和索赔数据的分析

期刊:Rheumatology and Therapy
影响因子:2.9
doi:10.1007/s40744-019-0139-5
Gale, Sara; Trinh, Huong; Tuckwell, Katie; Collinson, Neil; Stone, John H; Sarsour, Khaled; Pei, Jinglan; Best, Jennie; Birchwood, Christine; Mohan, Shalini V
关节炎
细胞生物学
发表日期：2019
文献求助 收藏

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial

奥克瑞珠单抗可减缓原发性进展型多发性硬化症患者上肢功能障碍的进展：来自 III 期随机 ORATORIO 试验的结果

期刊:Multiple Sclerosis Journal
影响因子:5
doi:10.1177/1352458518808189
Fox, Edward J; Markowitz, Clyde; Applebee, Angela; Montalban, Xavier; Wolinsky, Jerry S; Belachew, Shibeshih; Fiore, Damian; Pei, Jinglan; Musch, Bruno; Giovannoni, Gavin
神经科学
多发性硬化症
发表日期：2018
文献求助 收藏

Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis

静脉注射或皮下注射托珠单抗对类风湿性关节炎患者自述生活质量结局的影响

期刊:RMD Open
影响因子:4.7
doi:10.1136/rmdopen-2017-000602
Strand, Vibeke; Michalska, Margaret; Birchwood, Christine; Pei, Jinglan; Tuckwell, Katie; Finch, Rebecca; Kivitz, Alan J; Smolen, Josef S; Burmester, Gerd R
关节炎
发表日期：2018
文献求助 收藏

Long-Term Safety of Rituximab in Rheumatoid Arthritis: Analysis From the SUNSTONE Registry

利妥昔单抗治疗类风湿性关节炎的长期安全性：来自 SUNSTONE 注册研究的分析

期刊:Arthritis Care & Research
影响因子:3.3
doi:10.1002/acr.23781
Winthrop, Kevin L; Saag, Kenneth; Cascino, Matthew D; Pei, Jinglan; John, Ani; Jahreis, Angelika; Haselkorn, Tmirah; Furst, Daniel E
关节炎
发表日期：2018
文献求助 收藏